The Timeline of Value Creation and ACT Engagement

Standalone Value Creation

Engagement With ACT

March 9, 2023

Formation of Strategy Committee, composed of outside directors, focused on maximizing mid- to long-term corporate and shareholder value.

March 9, 2023

Formation of Strategy Committee, composed of outside directors, focused on maximizing mid- to long-term corporate and shareholder value.

April 10, 2024

Announcement of recommendations made by the Strategy Committee

  • Concrete action plans to accelerate growth
  • Changes to the group structure that will enhance long-term growth and corporate value
  • Enhancement of investor engagement
April 10, 2024

Announcement of recommendations made by the Strategy Committee

  • Concrete action plans to accelerate growth
  • Changes to the group structure that will enhance long-term growth and corporate value
  • Enhancement of investor engagement
August 8, 2024

Immediately formed Special Committee to review offer

August 8, 2024

Immediately formed Special Committee to review offer

September 6, 2024

Expressed openness to consider further proposals

September 6, 2024

Expressed openness to consider further proposals

October 4, 2024

Requested a meeting with ACT to discuss how the companies could address competition concerns

October 4, 2024

Requested a meeting with ACT to discuss how the companies could address competition concerns

October 10, 2024

Announced the plan to achieve a new group structure in which the CVS, SST and financial services, each have capital and strategic independence

October 10, 2024

Announced the plan to achieve a new group structure in which the CVS, SST and financial services, each have capital and strategic independence

October 16, 2024

Proactively shared draft non-disclosure agreement (NDA) and joint defense agreement (JDA) to advance discussions

October 16, 2024

Proactively shared draft non-disclosure agreement (NDA) and joint defense agreement (JDA) to advance discussions

October 24, 2024

Announced medium-term growth strategy of each business with key KPIs to FY30E

October 24, 2024

Announced medium-term growth strategy of each business with key KPIs to FY30E

November 30, 2024

• During legal discussions, 7&i proposed multiple routes to regulatory approval

• Requested that ACT provide concrete antitrust proposal

November 30, 2024

• During legal discussions, 7&i proposed multiple routes to regulatory approval

• Requested that ACT provide concrete antitrust proposal

January 9, 2025

Announced progress on key strategic initiatives of each business

• Continue to pursue growth by focusing on CVS business

January 9, 2025

Announced progress on key strategic initiatives of each business

• Continue to pursue growth by focusing on CVS business

January 11, 2025

Held meeting with ACT to discuss transaction terms and operations policies after the transaction

January 11, 2025

Held meeting with ACT to discuss transaction terms and operations policies after the transaction

February 5, 2025

Delivered second proposal to sign NDA with suitable protections and outlining a divestiture plan

February 5, 2025

Delivered second proposal to sign NDA with suitable protections and outlining a divestiture plan

March 6, 2025

Announced plan to unlock shareholder value through leadership changes and transformational capital and business initiatives

• Announced sale of Superstore Business Group to Bain Capital

• Announced deconsolidation of Seven Bank, targeting completion in FY25E

March 6, 2025

Announced plan to unlock shareholder value through leadership changes and transformational capital and business initiatives

• Announced sale of Superstore Business Group to Bain Capital

• Announced deconsolidation of Seven Bank, targeting completion in FY25E

May 1, 2025

Announced the signing of an NDA including a “standstill” provision while cautioning that it remains critical for the Special Committee to assess if there is a path to a viable divesture that will satisfy regulators.

May 1, 2025

Announced the signing of an NDA including a “standstill” provision while cautioning that it remains critical for the Special Committee to assess if there is a path to a viable divesture that will satisfy regulators.